Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.
Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.
A large part of the funding will go to the research and development of CIN-107 as it has shown the potential to treat primary aldosteronism and treatment-resistant hypertension.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
GSK shares are climbing in premarket trading on rumors that the company’s consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
Two months after J&J CEO Alex Gorsky announced plans to step down, Chief Scientific Officer Paul Stoffels will retire from the life sciences giant at the end of the year.
Variety, passion and the ability to make tangible improvements in people’s lives have propelled John Fowler, co-founder and CEO of Kezar Life Sciences, throughout his career.
The scenery will continue to change for GlaxoSmithKline as the company’s planned demerger looms on the horizon. On Monday, GSK gave a glimpse of where the companies will call home post-split.
Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO.